PL1792626T3 - Leczenie otyłości ciałami mimetycznymi alfa-MSH - Google Patents
Leczenie otyłości ciałami mimetycznymi alfa-MSHInfo
- Publication number
- PL1792626T3 PL1792626T3 PL06255194T PL06255194T PL1792626T3 PL 1792626 T3 PL1792626 T3 PL 1792626T3 PL 06255194 T PL06255194 T PL 06255194T PL 06255194 T PL06255194 T PL 06255194T PL 1792626 T3 PL1792626 T3 PL 1792626T3
- Authority
- PL
- Poland
- Prior art keywords
- mimetibodies
- msh
- obesity
- alpha
- treatment
- Prior art date
Links
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 title 1
- 101710200814 Melanotropin alpha Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/245,653 US7790671B2 (en) | 2005-10-07 | 2005-10-07 | Implantable pump for protein delivery for obesity control by drug infusion into the brain |
| EP06255194A EP1792626B1 (en) | 2005-10-07 | 2006-10-09 | Treatment of obesity with alpha-MSH mimetibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1792626T3 true PL1792626T3 (pl) | 2012-10-31 |
Family
ID=37823711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06255194T PL1792626T3 (pl) | 2005-10-07 | 2006-10-09 | Leczenie otyłości ciałami mimetycznymi alfa-MSH |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7790671B2 (pl) |
| EP (1) | EP1792626B1 (pl) |
| AU (1) | AU2006225291B2 (pl) |
| CA (1) | CA2562767C (pl) |
| PL (1) | PL1792626T3 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| US8476227B2 (en) * | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
| US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
| US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0671781B2 (ja) * | 1987-12-29 | 1994-09-14 | 川崎製鉄株式会社 | 加工性の良好な塗装焼付用複合鋼板およびその製造方法 |
| US5110596A (en) * | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
| US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
| US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
| US6406697B1 (en) * | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5286789A (en) * | 1989-05-26 | 1994-02-15 | Applied Immune Sciences, Inc. | Solid phase multiple peptide synthesis |
| DE4137649C2 (de) * | 1991-11-15 | 1997-11-20 | Gerhard Dingler | Bauelement |
| US5532347A (en) * | 1992-04-10 | 1996-07-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | DNA encoding α melanocyte stimulating hormone receptor |
| US5368588A (en) * | 1993-02-26 | 1994-11-29 | Bettinger; David S. | Parenteral fluid medication reservoir pump |
| US5697975A (en) * | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
| US5622860A (en) * | 1994-02-17 | 1997-04-22 | The Regents Of The University Of Michigan | Genes encoding melanocortin receptors |
| EP0788351B1 (en) * | 1994-11-10 | 2003-02-05 | The University of Kentucky Research Foundation | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
| US6132420A (en) * | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
| NZ331186A (en) * | 1996-02-02 | 2000-04-28 | Alza Corp | Osmotically driven sustained delivery drug delivery capsule |
| US6395292B2 (en) * | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6156331A (en) * | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US5976109A (en) * | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
| US5908609A (en) * | 1996-06-10 | 1999-06-01 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
| US5932779A (en) | 1996-06-10 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
| AU1623099A (en) * | 1997-12-22 | 1999-07-12 | Alza Corporation | Rate controlling membranes for controlled drug delivery devices |
| KR100568917B1 (ko) * | 1997-12-30 | 2006-04-07 | 알자 코포레이션 | 멤브레인 플러그를 갖는 익제 전달장치 |
| US6248112B1 (en) * | 1998-09-30 | 2001-06-19 | C. R. Bard, Inc. | Implant delivery system |
| US6716810B1 (en) * | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| EP1137340A4 (en) | 1998-12-09 | 2005-12-21 | Eleanor Roosevelt Inst | COMPOSITION AND METHODS FOR REGULATION OF BODY WEIGHT AND ASSOCIATED PATHOLOGIES |
| US6436091B1 (en) * | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| US6283949B1 (en) * | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
| WO2003104761A2 (en) | 2002-06-11 | 2003-12-18 | Auckland Uniservices Limited | Measurement of melanocortin peptides and uses thereof |
| US7241733B2 (en) * | 2002-06-28 | 2007-07-10 | Centocor, Inc. | Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses |
| US20050186608A1 (en) | 2004-02-19 | 2005-08-25 | Olsen Byron V. | Method for the production of transgenic proteins useful in the treatment of obesity and diabetes |
| WO2006036922A2 (en) | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| RS51789B (sr) | 2004-10-25 | 2011-12-31 | Centocor Ortho Biotech Inc. | Mimetička tela koja vezuju receptore melanokortina, smese, postupci i upotrebe |
| US20060188496A1 (en) | 2005-02-23 | 2006-08-24 | Hanne Bentz | Intranasal administration of active agents to the central nervous system |
-
2005
- 2005-10-07 US US11/245,653 patent/US7790671B2/en not_active Expired - Fee Related
-
2006
- 2006-10-06 AU AU2006225291A patent/AU2006225291B2/en not_active Ceased
- 2006-10-06 CA CA2562767A patent/CA2562767C/en not_active Expired - Fee Related
- 2006-10-09 PL PL06255194T patent/PL1792626T3/pl unknown
- 2006-10-09 EP EP06255194A patent/EP1792626B1/en not_active Not-in-force
-
2010
- 2010-02-22 US US12/709,920 patent/US8252744B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2562767A1 (en) | 2007-04-07 |
| EP1792626B1 (en) | 2012-05-23 |
| EP1792626A1 (en) | 2007-06-06 |
| US7790671B2 (en) | 2010-09-07 |
| US8252744B2 (en) | 2012-08-28 |
| AU2006225291A1 (en) | 2007-04-26 |
| CA2562767C (en) | 2014-06-03 |
| AU2006225291B2 (en) | 2012-08-30 |
| US20100183700A1 (en) | 2010-07-22 |
| US20070082843A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188746A0 (en) | Treatment of cancer | |
| IL191379A (en) | sewage care | |
| ZA200800464B (en) | Peptides for use in the treatment of obesity | |
| GB0602178D0 (en) | Therapeutic treatment | |
| HUS1800006I1 (hu) | Alfa-MSH származékok fotodermatózisok kezelésére | |
| IL186408A0 (en) | Combination treatment methods | |
| GB0624874D0 (en) | Treatment | |
| ZA200901452B (en) | Treatment of vertigo with acetyl-L-leucine | |
| GB0600692D0 (en) | Well treatment | |
| GB0608655D0 (en) | Therapeutic Treatment | |
| GB0502656D0 (en) | Treatment of metakaolin | |
| PL1792626T3 (pl) | Leczenie otyłości ciałami mimetycznymi alfa-MSH | |
| GB0516068D0 (en) | Well treatment | |
| GB0610909D0 (en) | Therapeutic treatment | |
| GB0511769D0 (en) | Treatment | |
| GB0607952D0 (en) | Novel treatment | |
| EP1942911A4 (en) | THERAPEUTIC MOLECULES AND USES THEREOF | |
| EP1973558A4 (en) | METHODS OF TREATING OBESITY WITH ENTEROSTATIN | |
| GB0604460D0 (en) | Treatment | |
| GB0520067D0 (en) | Treatment of cancer | |
| GB0502171D0 (en) | Well treatment | |
| GB0525535D0 (en) | Tumour treatment | |
| GB0602857D0 (en) | The treatment of sialorrhoea | |
| GB0512646D0 (en) | Treatment of gases | |
| GB0610376D0 (en) | Therapeutic treatment |